868 related articles for article (PubMed ID: 29267280)
1. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
[TBL] [Abstract][Full Text] [Related]
2. Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies.
Scalise ML; Arrúa EC; Rial MS; Esteva MI; Salomon CJ; Fichera LE
Am J Trop Med Hyg; 2016 Aug; 95(2):388-93. PubMed ID: 27246447
[TBL] [Abstract][Full Text] [Related]
3. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
[TBL] [Abstract][Full Text] [Related]
4. Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection.
Rial MS; Scalise ML; López Alarcón M; Esteva MI; Búa J; Benatar AF; Prado NG; Riarte AR; Fichera LE
Parasitology; 2019 Mar; 146(3):305-313. PubMed ID: 30301480
[TBL] [Abstract][Full Text] [Related]
5. Trypanosoma cruzi: Immunological predictors of benznidazole efficacy during experimental infection.
Fernández MC; González Cappa SM; Solana ME
Exp Parasitol; 2010 Feb; 124(2):172-80. PubMed ID: 19747482
[TBL] [Abstract][Full Text] [Related]
6. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
[TBL] [Abstract][Full Text] [Related]
7. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
[TBL] [Abstract][Full Text] [Related]
8. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
Cevey ÁC; Mirkin GA; Penas FN; Goren NB
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
[TBL] [Abstract][Full Text] [Related]
9. Low-dose of benznidazole promotes therapeutic cure in experimental chronic Chagas' disease with absence of parasitism in blood, heart and colon.
Perin L; Fonseca KDS; de Carvalho TV; Carvalho LM; Madeira JV; Medeiros LDF; Molina I; Correa-Oliveira R; Carneiro CM; Vieira PMA
Exp Parasitol; 2020 Mar; 210():107834. PubMed ID: 31978394
[TBL] [Abstract][Full Text] [Related]
10. Trypanosoma cruzi: Does the intake of nanoencapsulated benznidazole control acute infections?
Dutra da Silva A; Fracasso M; Bottari NB; Gundel S; Ourique AF; Assmann CE; Ferreira DASP; Castro MFV; Reichert KP; de Souza LAF; da Veiga ML; da Rocha MIUM; Monteiro SG; Morsch VM; Chitolina Schetinger MR; da Silva AS
Exp Parasitol; 2023 Jun; 249():108520. PubMed ID: 37001581
[TBL] [Abstract][Full Text] [Related]
11. Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment.
Aguilera E; Varela J; Serna E; Torres S; Yaluff G; Bilbao NV; Cerecetto H; Alvarez G; González M
Mem Inst Oswaldo Cruz; 2018 Mar; 113(3):153-160. PubMed ID: 29412353
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
[TBL] [Abstract][Full Text] [Related]
13. Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.
Seguel V; Castro L; Reigada C; Cortes L; Díaz MV; Miranda MR; Pereira CA; Lapier M; Campos-Estrada C; Morello A; Kemmerling U; Maya JD; López-Muñoz R
Exp Parasitol; 2016 Dec; 171():23-32. PubMed ID: 27729250
[TBL] [Abstract][Full Text] [Related]
14. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease.
Francisco AF; Jayawardhana S; Taylor MC; Lewis MD; Kelly JM
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082291
[TBL] [Abstract][Full Text] [Related]
16. Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease.
Assíria Fontes Martins T; de Figueiredo Diniz L; Mazzeti AL; da Silva do Nascimento ÁF; Caldas S; Caldas IS; de Andrade IM; Ribeiro I; Bahia MT
PLoS One; 2015; 10(6):e0128707. PubMed ID: 26076455
[TBL] [Abstract][Full Text] [Related]
17. Benznidazole/Poloxamer 407 Solid Dispersion as a New Strategy to Improve the Treatment of Experimental Trypanosoma cruzi Infection.
Davies C; Simonazzi A; Micheloud JF; Ragone PG; Cid AG; Negrette OS; Bermúdez JM; Parada LA
J Parasitol; 2020 Jun; 106(3):323-333. PubMed ID: 32369594
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.
Torchelsen FKVDS; Silva TM; Milagre MM; Silva RR; Reis LES; Branquinho RT; Silva GN; de Lana M
Parasitol Res; 2021 Apr; 120(4):1511-1517. PubMed ID: 33236174
[TBL] [Abstract][Full Text] [Related]
19. Frequency Variation and Dose Modification of Benznidazole Administration for the Treatment of Trypanosoma cruzi Infection in Mice, Dogs, and Nonhuman Primates.
Bustamante JM; White BE; Wilkerson GK; Hodo CL; Auckland LD; Wang W; McCain S; Hamer SA; Saunders AB; Tarleton RL
Antimicrob Agents Chemother; 2023 May; 67(5):e0013223. PubMed ID: 37039666
[TBL] [Abstract][Full Text] [Related]
20. Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.
Li X; Yi S; Scariot DB; Martinez SJ; Falk BA; Olson CL; Romano PS; Scott EA; Engman DM
JCI Insight; 2021 May; 6(9):. PubMed ID: 33986194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
